Skadden has advised Vaxcyte, Inc. Latham & Watkins LLP has advised the underwriters. Vaxcyte, Inc. has completed the closing of an underwritten public offering of 12,650,000...
Vaxcyte Completes $632.5 Million Public Offering of Common Stock
Korro Bio and Frequency Therapeutics’ Merger Agreement
Goodwin Procter is serving as legal counsel to Korro Bio, Latham & Watkins is serving as Frequency Therapeutics’ legal counsel, and Davis Polk is serving as...
US Foods Holding Corp’s Secondary Public Offering of Common Stock
Latham & Watkins’ capital markets team represents the underwriter in the offering by the leading foodservice distributor. US Foods Holding Corp. has announced the pricing of a...
BridgeBio Pharma’s $150 Million Common Stock Public Offering
Goodwin Procter advised BridgeBio Pharma on the offering, and Latham & Watkins advised the underwriters involved. BridgeBio Pharma, Inc. announced the pricing on March 7, 2023 of...
Revolution Medicines’ $345 Million Common Stock Public Offering
Latham & Watkins is advising Revolution Medicines on the offering, and Davis Polk is advising the underwriters involved. Revolution Medicines, Inc. (Nasdaq: RVMD) has announced the...
Indivior’s $145 Million Acquisition of Opiant Pharmaceuticals
Covington & Burling LLP advised Indivior, while Latham & Watkins LLP represented Opiant in the transaction. Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) has entered into a definitive...
Nordic Capital’s Investment Into Equashield
Latham & Watkins LLP represented Nordic Capital in the transaction. Nordic Capital, a leading private equity investor, and Equashield have announced that Nordic Capital has joined Equashield’s...
MeiraGTx’s Growth Financing Agreement with Perceptive Advisors
Latham & Watkins represented MeiraGTx in the transaction. MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage gene therapy company, announced a financing agreement with affiliates...
Revolution Medicines’ $230 Million Shares Offering
Latham & Watkins represented Revolution Medicines, while Davis Polk advised the underwriters in the offering. Revolution Medicines, Inc. (Nasdaq: RVMD), has announced the pricing of its underwritten...
CooperCompanies’ Acquisition of Cook Medical’s Reproductive Health Business
Latham & Watkins represented CooperCompanies in the transaction. CooperCompanies has announced it has signed a binding letter of intent to acquire Cook Medical’s Reproductive Health business, a manufacturer...
Lyell Immunopharma’s $425 Million Initial Pubic Offering
Latham & Watkins Advises the Underwriters in the offering while Cooley LLP represented Lyell Immunopharma. Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company...